Sign In
Buy CANF
$3.15
-0.130 (-3.96%)
At Close: Jul 31, 2026
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
07:00am, Monday, 11'th Nov 2024
Orphan Drug Designation has been granted lately by US FDA RAMAT GAN, Israel, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advan
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
07:08am, Monday, 04'th Nov 2024
Namodenoson is an oral drug with a proven favorable safety profile RAMAT GAN, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology c
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
09:06am, Friday, 18'th Oct 2024
Data Reported by Can-Fite Veterinary Partner Vetbiolix who already exercised its option for a full license deal worth $325M
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
07:00am, Wednesday, 09'th Oct 2024
RAMAT GAN, Israel, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that a
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
08:15am, Thursday, 29'th Aug 2024
RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that a
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 09'th Aug 2024
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE American:OSTX) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip Small Stoc
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
07:01pm, Thursday, 08'th Aug 2024
RAMAT GAN, Israel, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that a
Can-Fite Provides Namodenoson Patent Update
07:00am, Monday, 29'th Jul 2024
Broad Protection of Namodenoson is expected till at least 2044 PETACH TIKVA, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology comp
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
07:00am, Wednesday, 17'th Jul 2024
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs tha
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer
07:00am, Thursday, 11'th Jul 2024
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs tha
Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver
07:00am, Monday, 24'th Jun 2024
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre
Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study
07:00am, Monday, 10'th Jun 2024
PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre
Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study
07:00am, Wednesday, 05'th Jun 2024
RAMAT GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address o
Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases
07:00am, Wednesday, 29'th May 2024
RAMAT-GAN, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address
